Repertoire Immune Medicines announced a strategic collaboration with Eli Lilly to develop tolerization therapies for autoimmune diseases[1]. The goal of the collaboration is the treatment of several autoimmune diseases through new immunological drugs[1]. Repertoire uses its proprietary DECODE platform, which analyzes T-cells and their interactions in the adaptive immune system[1]. This platform enables the discovery of immune response codes and the design of targeted immunotherapies[1]. The company focuses on the development of transformative immunological medicines for patients with cancer and autoimmune diseases[1]. In the field of autoimmune diseases, it generates a new class of immunological drugs[1]. Collaboration with Lilly strengthens the development of tolerizing therapies that program the immune system[1].